Move your CNS program to IND with confidence

The blood-brain barrier, translational complexity, and fragmented vendor stacks are the three most common causes of Investigational New Drug (IND) delays in Central Nervous System (CNS) programs. Labcorp’s nonclinical portfolio connects CNS safety pharmacology, GLP toxicology, PK/PD, brain and CSF bioanalysis, and translational biomarkers into one coordinated program, enabling you to generate decision-grade data faster and submit with confidence.